FamiCord AG
2.74
EUR
-0.11
(-3.86%)
ISIN
DE000A0BL849
Return %
Stock
S&P 500
1Y
-52.35
14.20
3Y
-41.58
81.12
5Y
-81.73
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Jakub Julian Baran
- Full Time Employees
- 742
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Perlickstrasse 5 Leipzig SX Germany 04103
- IPO Date
- Nov 21, 2007
- Website
- famicord.com
- Similar Companies
- Business
- FamiCord AG operates as a leading stem cell bank specializing primarily in the collection, processing, and long-term storage of umbilical cord blood and tissue stem cells. Its core offerings include family cord blood banking services; placenta-derived mesenchymal stem cell (MSC) banking; processing and storage of perinatal tissue stem cells; and production of cell-based therapeutic products. The company serves a broad range of markets across Europe, the Middle East, and selected Asian regions through a network of subsidiaries and affiliated companies. Founded in 2003 and headquartered in Leipzig, Germany, FamiCord has expanded its operations through strategic acquisitions, including majority stakes in stem cell banks in Eastern Europe and strengthening its market presence in GCC countries and Hong Kong. In recent developments, FamiCord AG significantly increased its revenue by 14.6 percent to €43.6 million and boosted EBITDA from continuing operations by 36.2 percent to €5.0 million in the first half of 2025. The company reaffirmed its strategic focus on its core cord blood banking business, discontinuing the prioritization of proprietary CAR-T cell therapy development, which it has transferred to minority shareholders and external investors while excluding related activities from its group EBITDA going forward. Key acquisitions include increasing its stake in subsidiaries operating in Slovakia and the Czech Republic from 26 percent to 95 percent, enabling full consolidation and deeper penetration in Eastern European markets. The company also continues to expand its technical infrastructure and recently rebranded under the unified FamiCord name, reinforcing its position as Europe's largest stem cell bank and emphasizing profitability and sustainable growth as priorities. FamiCord’s business segments encompass B2C end-customer services, notably family stem cell banking, alongside B2B collaborations supplying biological materials and supporting the development of cell therapy products through its contract development and manufacturing organization (CDMO) services. Its customer base ranges from individual families seeking long-term stem cell storage to biotech firms requiring development and manufacturing support for cellular therapies. Geographically, the company holds leading market shares in Europe, with substantial operations in Germany, Poland, the Czech Republic, Slovakia, and Portugal, and key growth markets in the GCC region. As of 2025, FamiCord manages over one million stored stem cell samples, operates 13 processing and 2 storage laboratories, and commands approximately 55 percent market share in Europe, positioning it as a top-three global player in the stem cell banking industry. FamiCord AG maintains a vigorous M&A-driven growth strategy, having completed around 30 acquisitions since inception and continuously integrating established stem cell banks across Europe and select international markets. The company’s enhanced operational scale and redefined strategic priorities aim to restore profitability and financial strength amid challenging market conditions, including demographic pressures and geopolitical uncertainties. The leadership underscores regionally differentiated sales and strict cost control as critical for future growth. The company is listed on the Frankfurt Stock Exchange under the ticker V3V.DE and operates under a prime standard regulatory regime. Overall, FamiCord AG presents a comprehensive platform providing advanced stem cell banking solutions, related therapeutic products, and supporting services with a broad geographic footprint and a strong emphasis on core operations and profitable growth in the evolving regenerative medicine market.
Company News
FamiCord AG - Special Call